Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 28

1.

Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial.

Fabbiani M, Di Giambenedetto S, Quiros-Roldan E, Latini A, Vullo V, Antinori A, Castagna A, Orofino G, Francisci D, Grilli E, Madeddu G, Grima P, Rusconi S, Del Pin B, Mondi A, Borghetti A, Focà E, Colafigli M, De Luca A, Cauda R.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19808. doi: 10.7448/IAS.17.4.19808. eCollection 2014.

2.

Elderly women with human immunodeficiency virus infection: is there an effect of the virus on neuropsychological profile?

Sorlini ML, Focà E, Motta D, Salvi A, Compostella S, Brianese N, Ferraresi A, Casari S, Romanelli G, Castelli F, Quiros Roldan E.

J Am Geriatr Soc. 2014 Jan;62(1):194-6. No abstract available.

PMID:
25180386
3.

Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection.

Porcelli T, Gotti D, Cristiano A, Maffezzoni F, Mazziotti G, Focà E, Castelli F, Giustina A, Quiros-Roldan E.

Osteoporos Int. 2014 Sep;25(9):2263-9. doi: 10.1007/s00198-014-2760-z. Epub 2014 Jul 24.

PMID:
25056799
4.

The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study.

Bellino S, Tripiciano A, Picconi O, Francavilla V, Longo O, Sgadari C, Paniccia G, Arancio A, Angarano G, Ladisa N, Lazzarin A, Tambussi G, Nozza S, Torti C, Focà E, Palamara G, Latini A, Sighinolfi L, Mazzotta F, Di Pietro M, Di Perri G, Bonora S, Mercurio VS, Mussini C, Gori A, Galli M, Monini P, Cafaro A, Ensoli F, Ensoli B.

Retrovirology. 2014 Jun 24;11:49. doi: 10.1186/1742-4690-11-49.

5.

Survival in HIV-infected patients after a cancer diagnosis in the cART Era: results of an italian multicenter study.

Gotti D, Raffetti E, Albini L, Sighinolfi L, Maggiolo F, Di Filippo E, Ladisa N, Angarano G, Lapadula G, Pan A, Esposti AD, Fabbiani M, Focà E, Scalzini A, Donato F, Quiros-Roldan E; Master Cohort Group.

PLoS One. 2014 Apr 23;9(4):e94768. doi: 10.1371/journal.pone.0094768. eCollection 2014.

6.

Clinical and immunological outcomes according to adherence to first-line HAART in a urban and rural cohort of HIV-infected patients in Burkina Faso, West Africa.

Focà E, Odolini S, Sulis G, Calza S, Pietra V, Rodari P, Giorgetti PF, Noris A, Ouedraogo P, Simpore J, Pignatelli S, Castelli F.

BMC Infect Dis. 2014 Mar 21;14:153. doi: 10.1186/1471-2334-14-153.

7.

For timing of HAART is less more? CD4+/CD8+ ratio and CD4+ percentage as surrogate markers for more complex immunological features.

Fogli M, Iaria M, Focá E, Giagulli C, Caccuri F, Maggi F, Torti C, Caruso A, Fiorentini S.

New Microbiol. 2014 Jan;37(1):75-80. Epub 2014 Jan 15.

8.

Evaluation of boosted and unboosted atazanavir plasma concentration in HIV infected patients.

Amadasi S, Odolini S, Foca E, Panzali A, Cerini C, Lonati L, Pezzoli MC, Nasta P, Casari S, Castelli F, Quiros-Roldan E.

Curr HIV Res. 2013 Dec;11(8):642-6.

PMID:
24517189
9.

Synthetic HIV-1 matrix protein p17-based AT20-KLH therapeutic immunization in HIV-1-infected patients receiving antiretroviral treatment: A phase I safety and immunogenicity study.

Iaria ML, Fiorentini S, Focà E, Zicari S, Giagulli C, Caccuri F, Francisci D, Di Perri G, Castelli F, Baldelli F, Caruso A.

Vaccine. 2014 Feb 19;32(9):1072-8. doi: 10.1016/j.vaccine.2013.12.051. Epub 2014 Jan 20.

PMID:
24456624
10.

Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial.

Rusconi S, Vitiello P, Adorni F, Colella E, Focà E, Capetti A, Meraviglia P, Abeli C, Bonora S, D'Annunzio M, Di Biagio A, Di Pietro M, Butini L, Orofino G, Colafigli M, d'Ettorre G, Francisci D, Parruti G, Soria A, Buonomini AR, Tommasi C, Mosti S, Bai F, Di Nardo Stuppino S, Morosi M, Montano M, Tau P, Merlini E, Marchetti G.

PLoS One. 2013 Nov 14;8(11):e80157. doi: 10.1371/journal.pone.0080157. eCollection 2013.

11.

Kidney disease in HIV-infected patients.

Scarpino M, Pinzone MR, Di Rosa M, Madeddu G, Focà E, Martellotta F, Schioppa O, Ceccarelli G, Celesia BM, d'Ettorre G, Vullo V, Berretta S, Cacopardo B, Nunnari G.

Eur Rev Med Pharmacol Sci. 2013 Oct;17(19):2660-7. Review.

12.

Vitamin D deficiency in HIV infection: an underestimated and undertreated epidemic.

Pinzone MR, Di Rosa M, Malaguarnera M, Madeddu G, Focà E, Ceccarelli G, d'Ettorre G, Vullo V, Fisichella R, Cacopardo B, Nunnari G.

Eur Rev Med Pharmacol Sci. 2013 May;17(9):1218-32. Review.

13.

Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-naïve patients prescribed efavirenz compared to atazanavir/ritonavir.

Gotti D, Cesana BM, Albini L, Calabresi A, Izzo I, Focà E, Motta D, Bellagamba R, Fezza R, Narciso P, Sighinolfi L, Maggi P, Brianese N, Quiros-Roldan E, Guaraldi G, Torti C.

HIV Clin Trials. 2012 Sep-Oct;13(5):245-55. doi: 10.1310/hct1305-245.

PMID:
23134625
14.

Malaria and hiv in adults: when the parasite runs into the virus.

Focà E, Odolini S, Brianese N, Carosi G.

Mediterr J Hematol Infect Dis. 2012;4(1):e2012032. doi: 10.4084/MJHID.2012.032. Epub 2012 May 7.

15.

Impact of detectable human cytomegalovirus DNAemia on viro-immunological effectiveness of HAART in HIV-infected patients naive to antiretroviral therapy.

Focà E, Motta D, Pollara C, Brianese N, Gotti D, Albini L, Quiros-Roldan E, Torti C, Manca N.

New Microbiol. 2012 Apr;35(2):227-31. Epub 2012 Mar 31.

16.

Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received.

Motta D, Brianese N, Focà E, Nasta P, Maggiolo F, Fabbiani M, Cologni G, Di Giambenedetto S, Di Pietro M, Ladisa N, Sighinolfi L, Costarelli S, Castelnuovo F, Torti C.

AIDS Res Ther. 2012 Jun 15;9(1):18. doi: 10.1186/1742-6405-9-18.

17.

Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use.

Focà E, Ripamonti D, Motta D, Torti C.

Drugs. 2012 Jun 18;72(9):1161-73. doi: 10.2165/11631070-000000000-00000.

PMID:
22646049
18.

[HIV/AIDS care and international migrations in the rural district of Nanoro, Burkina Faso].

Autino B, Odolini S, Nitiema H, Kiema D, Melzani A, Pietra V, Martinetto M, Bettinzoli M, Simpore J, Sulis G, Focà E, Castelli F.

Bull Soc Pathol Exot. 2012 May;105(2):130-6. doi: 10.1007/s13149-012-0229-x. Epub 2012 Mar 28. French.

PMID:
22457020
19.

Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz.

Focà E, Motta D, Borderi M, Gotti D, Albini L, Calabresi A, Izzo I, Bellagamba R, Narciso P, Sighinolfi L, Clò A, Gibellini D, Quiros-Roldan E, Brianese N, Cesana BM, Re MC, Torti C.

BMC Infect Dis. 2012 Feb 14;12:38. doi: 10.1186/1471-2334-12-38.

20.

Asymptomatic neurocognitive disorders in patients infected by HIV: fact or fiction?

Torti C, Focà E, Cesana BM, Lescure FX.

BMC Med. 2011 Dec 28;9:138. doi: 10.1186/1741-7015-9-138.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk